Search Results

You are looking at 51 - 60 of 127 items for :

  • "papillary" x
  • Refine by Access: All x
Clear All
Full access

Peter E. Clark, Philippe E. Spiess, Neeraj Agarwal, Rick Bangs, Stephen A. Boorjian, Mark K. Buyyounouski, Jason A. Efstathiou, Thomas W. Flaig, Terence Friedlander, Richard E. Greenberg, Khurshid A. Guru, Noah Hahn, Harry W. Herr, Christopher Hoimes, Brant A. Inman, A. Karim Kader, Adam S. Kibel, Timothy M. Kuzel, Subodh M. Lele, Joshua J. Meeks, Jeff Michalski, Jeffrey S. Montgomery, Lance C. Pagliaro, Sumanta K. Pal, Anthony Patterson, Daniel Petrylak, Elizabeth R. Plimack, Kamal S. Pohar, Michael P. Porter, Wade J. Sexton, Arlene O. Siefker-Radtke, Guru Sonpavde, Jonathan Tward, Geoffrey Wile, Mary A. Dwyer, and Courtney Smith

. 9 , 10 A reduced (one-third) dose of BCG has been evaluated for the possible reduction of side effects. In a phase III study, 1,316 patients with intermediate- or high-risk Ta, T1 papillary carcinoma of the bladder were randomized to receive either

Full access

Peter E. Clark, Neeraj Agarwal, Matthew C. Biagioli, Mario A. Eisenberger, Richard E. Greenberg, Harry W. Herr, Brant A. Inman, Deborah A. Kuban, Timothy M. Kuzel, Subodh M. Lele, Jeff Michalski, Lance C. Pagliaro, Sumanta K. Pal, Anthony Patterson, Elizabeth R. Plimack, Kamal S. Pohar, Michael P. Porter, Jerome P. Richie, Wade J. Sexton, William U. Shipley, Eric J. Small, Philippe E. Spiess, Donald L. Trump, Geoffrey Wile, Timothy G. Wilson, Mary Dwyer, and Maria Ho

tumor is solid (sessile) or high grade, or suggests invasion into muscle, a CT scan or MRI of the abdomen and pelvis is recommended before the TURBT. Because the results of a CT scan rarely alter the management of tumors with a purely papillary

Full access

Stephen A. Brassell and Ashish M. Kamat

: 2050 – 2053 . 66. Rintala E Jauhiainen K Kaasinen E . Alternating mitomycin C and bacillus Calmette-Guerin instillation prophylaxis for recurrent papillary (stages Ta to T1) superficial bladder cancer . J Urol 1996 ; 156 : 56 – 59

Full access

Pablo Maroto, Georgia Anguera, Juan Maria Roldan-Romero, Maria Apellániz-Ruiz, Ferran Algaba, Jacqueline Boonman, Mark Nellist, Cristina Montero-Conde, Alberto Cascón, Mercedes Robledo, and Cristina Rodríguez-Antona

% of papillary and chromophobe subtypes have mutations in MTOR, TSC1 , or TSC2. 9 – 11 In addition, inactivation of PTEN is frequent in chRCC. Altogether, genomic targeting of the mTOR pathway occurs in 23% of chRCC cases, 11 , 12 suggesting

Full access

Mod C. Chandhanayingyong, Nicholas M. Bernthal, Piti Ungarreevittaya, Scott D. Nelson, Sant P. Chawla, and Arun S. Singh

subsequently confirmed with the R130Q mutation in her PTEN gene. In 2008, she had a complete hysterectomy with salpingo-oophorectomy for uterine fibroids, and in 2009 she had a complete thyroidectomy for multicystic adenomatous nodules with focal papillary

Full access

Henry G. Kaplan

present patient. In addition to increased stimulation by RAS, BRAF activity may be increased by the activating BRAF V600E mutation, which has now been identified in several tumor types, including 40% of papillary thyroid cancers, 10% to 65% of

Full access

Katherine Y. Fan, Avani S. Dholakia, Aaron T. Wild, Zheng Su, Amy Hacker-Prietz, Rachit Kumar, Mary Hodgin, Charles C. Hsu, Dung T. Le, Ana De Jesus-Acosta, Luis A. Diaz Jr, Daniel A. Laheru, Ralph H. Hruban, Elliot K. Fishman, Todd D. Brown, Timothy M. Pawlik, Christopher L. Wolfgang, Phuoc T. Tran, and Joseph M. Herman

), borderline resectable/locally advanced (BL), or metastatic (M) pancreatic cancer, or BPD. Diagnoses considered to be benign disease included autoimmune pancreatitis, intraductal papillary mucinous neoplasm, or pancreatic cyst. Exclusion criteria included

Full access

Victor T.G. Lin, Lisle M. Nabell, Sharon A. Spencer, William R. Carroll, Shuko Harada, and Eddy S. Yang

cancers, including high-grade colorectal neuroendocrine tumors, 22 papillary thyroid carcinoma, 23 and endometrial cancer. 24 To our knowledge, this is the first report of a patient with BRAF -mutated SDC treated with combined BRAF and MEK inhibition

Full access

Mark D. Tyson and Sam S. Chang

that they are at high risk of recurrence compared with those with pT1a tumors. Lastly, metachronous renal tumors in either the ipsilateral or contralateral kidney are found in as many as 20% of patients with papillary RCC or familial RCC. 14 Taken

Full access

Jennifer M. Weiss, Samir Gupta, Carol A. Burke, Lisen Axell, Lee-May Chen, Daniel C. Chung, Katherine M. Clayback, Susan Dallas, Seth Felder, Olumide Gbolahan, Francis M. Giardiello, William Grady, Michael J. Hall, Heather Hampel, Rachel Hodan, Gregory Idos, Priyanka Kanth, Bryson Katona, Laura Lamps, Xavier Llor, Patrick M. Lynch, Arnold J. Markowitz, Sara Pirzadeh-Miller, Niloy Jewel Samadder, David Shibata, Benjamin J. Swanson, Brittany M. Szymaniak, Georgia L. Wiesner, Andrew Wolf, Matthew B. Yurgelun, Mae Zakhour, Susan D. Darlow, Mary A. Dwyer, and Mallory Campbell

%–10%), thyroid cancer (1%–12%), gastric cancer (0.5%–1.3%), and hepatoblastoma (1%–2%, usually by age 5 years). 11 – 32 Most thyroid cancers seen in FAP are papillary thyroid carcinomas, with the rare cribriform-morular variant considered almost pathognomonic